CA
NZ
UK
AU
IND
US
…
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -19.90M | -15.10M | -23.66M | -47.67M | -26.68M |
| Net income | -19.95M | -15.12M | -23.69M | -47.39M | -26.85M |
| Selling general administrative | 46.62M | 39.97M | 45.93M | 52.02M | 44.54M |
| Selling and marketing expenses | - | 1.40M | 1.50M | - | - |
| Gross profit | 38.80M | 33.11M | 29.46M | 21.35M | 27.71M |
| Reconciled depreciation | 2.12M | 1.72M | 2.18M | 1.56M | 0.95M |
| Ebit | -15.58M | -12.87M | -21.32M | -40.55M | -24.07M |
| Ebitda | -13.46M | -11.14M | -19.15M | -39.72M | -24.05M |
| Depreciation and amortization | 2.12M | 1.72M | 2.17M | 0.83M | 0.02M |
| Non operating income net other | - | - | - | - | 0.02M |
| Operating income | -14.07M | -13.64M | -22.84M | -40.55M | -24.07M |
| Other operating expenses | 80.64M | 69.28M | 75.39M | 86.11M | 72.37M |
| Interest expense | 4.32M | 2.23M | 2.33M | 2.45M | 2.62M |
| Tax provision | 0.05M | 0.01M | 0.03M | -0.28M | 0.17M |
| Interest income | 0.29M | 0.77M | 1.52M | 0.83M | - |
| Net interest income | -4.03M | -1.47M | -1.56M | -1.62M | -2.62M |
| Income tax expense | 0.05M | 0.01M | 0.03M | -0.28M | 0.17M |
| Total revenue | 66.58M | 55.64M | 52.55M | 45.56M | 48.30M |
| Total operating expenses | 52.87M | 46.75M | 52.29M | 61.89M | 51.78M |
| Cost of revenue | 27.78M | 22.53M | 23.09M | 24.21M | 20.59M |
| Total other income expense net | -5.83M | -1.47M | -0.82M | -7.12M | -2.61M |
| Net income from continuing ops | -19.95M | -15.12M | -32.47M | -47.39M | -26.85M |
| Net income applicable to common shares | - | - | - | -47.39M | -26.85M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 58.02M | 44.69M | 56.94M | 86.22M | 123.44M |
| Other current assets | 5.82M | 0.86M | 1.93M | 4.14M | 3.64M |
| Total liab | 40.57M | 35.15M | 34.25M | 43.76M | 38.51M |
| Total stockholder equity | 17.45M | 9.54M | 22.69M | 42.46M | 84.94M |
| Other current liab | 6.33M | 8.95M | 7.04M | 5.35M | 6.24M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -314.28M | -294.33M | -279.22M | -255.53M | -208.14M |
| Other liab | - | - | - | 0.02M | 1.71M |
| Good will | - | - | - | 0.00M | 5.51M |
| Other assets | - | - | - | 0.53M | 0.43M |
| Cash | 32.22M | 22.04M | 36.49M | 62.39M | 99.44M |
| Total current liabilities | 14.16M | 13.51M | 11.90M | 9.62M | 9.32M |
| Current deferred revenue | 0.68M | - | - | - | - |
| Net debt | -6.51M | 0.97M | -12.77M | -27.89M | -71.96M |
| Short term debt | 3.00M | 0.42M | 1.73M | 1.23M | 0.59M |
| Short long term debt | 0.64M | 0.42M | 0.26M | 0.19M | - |
| Short long term debt total | 25.71M | 23.00M | 23.72M | 34.50M | 27.48M |
| Other stockholder equity | 331.71M | 303.85M | 301.89M | 297.97M | 293.06M |
| Property plant equipment | - | - | - | 13.08M | 4.77M |
| Total current assets | 48.89M | 36.45M | 47.84M | 72.61M | 112.73M |
| Net tangible assets | - | - | - | 42.46M | 79.43M |
| Net receivables | 10.86M | 7.83M | 6.55M | 6.08M | 9.65M |
| Long term debt | 22.26M | 19.82M | 19.23M | 28.78M | 27.48M |
| Inventory | - | - | 2.87M | 1.79M | 1.09M |
| Accounts payable | 4.15M | 4.14M | 3.13M | 3.05M | 2.49M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Common stock total equity | - | - | - | - | 0.02M |
| Retained earnings total equity | - | - | - | - | -208.14M |
| Non currrent assets other | 0.56M | 0.55M | 0.42M | 0.53M | 0.43M |
| Non current assets total | 9.13M | 8.23M | 9.10M | 13.61M | 10.71M |
| Capital lease obligations | 2.80M | 2.76M | 4.23M | 6.23M | 0.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.52M | -1.13M | -4.32M | -2.42M |
| Change to liabilities | - | - | - | 0.90M | 0.33M |
| Total cashflows from investing activities | -0.63M | -0.52M | -0.80M | -4.32M | -2.42M |
| Net borrowings | 2.88M | -0.86M | -10.94M | -0.70M | -0.53M |
| Total cash from financing activities | 24.43M | -0.66M | -10.63M | -0.49M | 64.68M |
| Change to operating activities | - | - | - | -2.81M | 1.34M |
| Net income | -19.95M | -15.12M | -23.69M | -47.39M | -26.85M |
| Change in cash | 10.18M | -14.46M | -25.90M | -36.95M | 41.99M |
| Begin period cash flow | 22.24M | 36.69M | 62.59M | 99.54M | 57.55M |
| End period cash flow | 32.42M | 22.24M | 36.69M | 62.59M | 99.54M |
| Total cash from operating activities | -13.62M | -13.28M | -14.46M | -32.14M | -20.27M |
| Issuance of capital stock | 22.02M | 0.00M | - | 0.00M | 69.14M |
| Depreciation | 2.12M | 1.72M | 2.17M | 1.56M | 0.95M |
| Other cashflows from investing activities | - | - | 0.02M | - | -0.05M |
| Dividends paid | - | - | 9.94M | - | -0.39M |
| Change to account receivables | -3.02M | -1.28M | -0.47M | 3.58M | -0.74M |
| Sale purchase of stock | - | 0.18M | 0.28M | 0.39M | 0.39M |
| Other cashflows from financing activities | - | 0.20M | 0.31M | -0.24M | -3.94M |
| Change to netincome | - | - | - | 11.86M | 5.42M |
| Capital expenditures | 0.64M | 0.52M | 0.83M | 4.32M | 2.37M |
| Change receivables | - | - | - | - | -0.74M |
| Cash flows other operating | - | - | - | - | 0.35M |
| Cash and cash equivalents changes | - | - | - | - | 41.99M |
| Change in working capital | -1.98M | -3.08M | 0.33M | 1.67M | -0.06M |
| Stock based compensation | 2.16M | 1.76M | 3.62M | 4.70M | 4.73M |
| Other non cash items | 4.03M | 1.43M | 3.12M | 7.62M | 0.82M |
| Free cash flow | -14.27M | -13.79M | -15.29M | -36.46M | -22.64M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| XGN Exagen Inc |
-0.82 9.64% |
7.69 | - | - | 2.55 | 14.62 | 2.53 | -0.16 |
| TMO Thermo Fisher Scientific Inc |
-14.58 2.06% |
691.58 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-4.36 1.86% |
230.57 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
26.96 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
- -% |
25.11 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Kamal Adawi M.S., MBA | CFO & Corp. Sec. | 1979 |
| Mr. John Aballi | CEO, Pres & Director | 1985 |
| Mr. Mark Hazeltine | Chief Bus. Officer & COO | 1974 |
| Dr. Ming-Chou Lee Ph.D. | Chief Technology Officer | NA |
| Ryan Douglas | Investors Relations Officer | NA |
| Mr. John Wegener | Sr. VP of Sales and Marketing | 1969 |
| Dr. Andrew L. Concoff FACR, M.D. | Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board | NA |
| Dr. Tina S. Nova Ph.D. | Executive Chairman of the Board of Directors | 1954 |
| Mr. John Aballi | CEO, President & Director | 1985 |
| Mr. Kamal Adawi M.S., MBA | CFO & Corporate Secretary | 1979 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.36%
Communication Services
-0.67%
Consumer Cyclical
-0.78%
Consumer Defensive
+0.21%
Energy
-0.60%
Financial Services
-0.86%
Financials
-0.33%
Healthcare
-1.71%
Industrials
-1.79%
Real Estate
-0.51%
Technology
-4.54%
Utilities
-0.28%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...